This study is accepting new patients by invitation only

Long-Term Follow-up Study

a study on Lymphoma Non-Hodgkin Lymphoma Hematologic Malignancy Multiple Myeloma Acute Myeloid Leukemia Leukemia Hematologic Neoplasms

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around

Description

Summary

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

Official Title

An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

Details

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. The purpose of this 15-year research study is to collect long-term observational data to identify and understand potential late side effects in these patients.

Keywords

Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia, Allogeneic CAR-T, CB-010, CB-011, CB-012, Multiple Myeloma, B-Cell Lymphoma, Hematologic Neoplasms, Allogeneic CAR-T therapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Written informed consent obtained prior to study-specific activities/enrollment
  • Received a Caribou allogeneic CAR-T therapy and completed or discontinued from a Caribou-sponsored study evaluating an allogeneic CAR-T therapy or was administered an allogeneic CAR-T therapy under a special access program or as part of an IIT

You CAN'T join if...

  • None

Locations

  • University of California Irvine
    Irvine California 92868 United States
  • University of California San Diego
    La Jolla California 92093 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Caribou Biosciences, Inc.
ID
NCT05332054
Study Type
Observational
Participants
Expecting 150 study participants
Last Updated